U.S. Markets close in 4 hrs 14 mins

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
33.225-0.135 (-0.405%)
As of 11:46AM EDT. Market open.
People also watch
MRKJNJJPMINTCGE
Full screen
Previous Close33.360
Open33.290
Bid33.260 x 1800
Ask33.270 x 9900
Day's Range33.195 - 33.450
52 Week Range29.830 - 35.380
Volume3,424,830
Avg. Volume19,421,421
Market Cap198.28B
Beta1.05
PE Ratio (TTM)27.97
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.84%)
Ex-Dividend Date2017-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
    Zacks2 hours ago

    Can Pfizer Bank on New Immunotherapy Bavencio for Growth?

    Pfizer, Inc.'s (PFE) newly approved anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant top-line driver for this New York-based pharma giant.

  • Market Realist4 hours ago

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

  • The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak
    InvestorPlaceyesterday

    The Bull Case for Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Weak

    Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.